Vestcor Inc Reduces Position in Medpace Holdings, Inc. $MEDP

Vestcor Inc trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 36.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,671 shares of the company’s stock after selling 1,528 shares during the period. Vestcor Inc’s holdings in Medpace were worth $1,373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quent Capital LLC acquired a new stake in shares of Medpace during the third quarter worth about $25,000. Optiver Holding B.V. acquired a new position in Medpace in the 3rd quarter worth approximately $27,000. Root Financial Partners LLC purchased a new position in Medpace during the 3rd quarter worth approximately $38,000. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Finally, Ameriflex Group Inc. lifted its stake in Medpace by 100.0% during the 3rd quarter. Ameriflex Group Inc. now owns 100 shares of the company’s stock valued at $51,000 after acquiring an additional 50 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

MEDP has been the topic of several recent research reports. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and dropped their price objective for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Mizuho set a $582.00 target price on shares of Medpace in a research report on Wednesday, February 11th. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Finally, Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a research note on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $486.67.

Medpace Stock Performance

MEDP stock opened at $477.72 on Thursday. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The firm’s fifty day moving average is $528.39 and its 200 day moving average is $539.24. The firm has a market cap of $13.56 billion, a PE ratio of 31.22, a P/E/G ratio of 2.24 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the prior year, the firm posted $3.67 earnings per share. The company’s revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.